A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the safety and tolerability of the
anti-VEGFR-2 monoclonal antibody ramucirumab drug product in combination with docetaxel in
Japanese participants with metastatic, or locally advanced breast cancer, with the aim of
confirming the recommended dose of ramucirumab drug product (DP) in combination with
docetaxel.